Rhabdomyosarcoma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Rhabdomyosarcoma - Pipeline Review, H2 2016

Rhabdomyosarcoma - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Rhabdomyosarcoma - Pipeline Review, H2 2016
Published Sep 30, 2016
147 pages — Published Sep 30, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Rhabdomyosarcoma Pipeline Review, H2 2016, provides an overview of the Rhabdomyosarcoma (Oncology) pipeline landscape.

Rhabdomyosarcoma (RMS) is a malignant tumor of connective tissue in which abnormal cells are thought to arise from primitive muscle cells. Symptoms include pain, fever, purplish discoloration of the eye, hearing loss, headaches, bulging of the eye, or a droopy eyelid and tingling or weakness. Predisposing factors include age, inherited conditions (neurofibromatosis type 1, Costello syndrome) and family history. Treatment includes surgery, chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Rhabdomyosarcoma Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Rhabdomyosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rhabdomyosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rhabdomyosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 7, 5, 2 and 1 respectively for Similarly, the Universities portfolio in Phase II and Discovery stages comprises 3 and 1 molecules, respectively for Rhabdomyosarcoma.

Rhabdomyosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Rhabdomyosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rhabdomyosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rhabdomyosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pip

  
Source:
Document ID
GMDHC8513IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables51
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
Rhabdomyosarcoma Overview81
Therapeutics Development92
  Pipeline Products for Rhabdomyosarcoma Overview91
  Pipeline Products for Rhabdomyosarcoma Comparative Analysis101
Rhabdomyosarcoma Therapeutics under Development by Companies111
Rhabdomyosarcoma Therapeutics under Investigation by Universities/Institutes121
Rhabdomyosarcoma Pipeline Products Glance132
  Clinical Stage Products131
  Early Stage Products141
Rhabdomyosarcoma Products under Development by Companies151
Rhabdomyosarcoma Products under Investigation by Universities/Institutes161
Rhabdomyosarcoma Companies Involved in Therapeutics Development1713
  Bellicum Pharmaceuticals, Inc.171
  Boehringer Ingelheim GmbH181
  Celgene Corporation191
  EpiZyme, Inc.201
  Exelixis, Inc.211
  Immunomedics, Inc.221
  Iproteos S.L.231
  Merrimack Pharmaceuticals, Inc.241
  Morphotek, Inc.251
  Novartis AG261
  Noxxon Pharma AG271
  Pfizer Inc.281
  Shionogi &Co., Ltd.291
Rhabdomyosarcoma Therapeutics Assessment3011
  Assessment by Monotherapy Products301
  Assessment by Target313
  Assessment by Mechanism of Action343
  Assessment by Route of Administration372
  Assessment by Molecule Type392
Drug Profiles41103
  afatinib dimaleate Drug Profile4113
  axitinib Drug Profile546
  cabozantinib s-malate Drug Profile6018
  Cellular Immunotherapy for GD2 Expressing Solid Tumors Drug Profile782
  Cellular Immunotherapy for Oncology Drug Profile802
  Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology Drug Profile821
  celyvir Drug Profile831
  crizotinib Drug Profile847
  everolimus Drug Profile9112
  Hex-hR1 Drug Profile1031
  irinotecan hydrochloride Drug Profile10411
  MAL-3101 Drug Profile1151
  NOXS-93 Drug Profile1161
  ontuxizumab Drug Profile1172
  paclitaxel albumin bound Drug Profile1198
  pazopanib hydrochloride Drug Profile1277
  S-588410 Drug Profile1342
  Synthetic Peptides for Rhabdomyosarcoma Drug Profile1361
  tazemetostat Drug Profile1377
Rhabdomyosarcoma Dormant Projects1441
Rhabdomyosarcoma Discontinued Products1451
Appendix1462
  Methodology1461
  Coverage1461
  Secondary Research1461
  Primary Research1461
  Expert Panel Validation1461
  Contact Us1461
  Disclaimer1471

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Rhabdomyosarcoma - Pipeline Review, H2 2016" Sep 30, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Rhabdomyosarcoma-Pipeline-Review-H2-2016-2088-16640>
  
APA:
Global Markets Direct - Market Research. (2016). Rhabdomyosarcoma - Pipeline Review, H2 2016 Sep 30, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Rhabdomyosarcoma-Pipeline-Review-H2-2016-2088-16640>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.